Is<sup>211</sup>At Really Happening?
Richard Zimmermann
Abstract
Beyond the 177Lu-based radiopharmaceuticals targeting somatostatin receptor and prostate-specific membrane antigen, there are new therapeutic radiopharmaceuticals that can potentially reach the market within the next 10 y. These molecules are labeled with 67Cu, 90Y, 131I, 161Tb, 188Re, 211At, 212Pb
Topics & Concepts
HappeningHistoryArt historyPerformance artAmino Acid Enzymes and MetabolismGenomics and Rare DiseasesRadiopharmaceutical Chemistry and Applications